2020-11-16T15:16:22-06:00 2019-12-31 410746749 CLIFTONLARSONALLEN LLP 610 W GERMANTOWN PIKE SUITE 400 PLYMOUTH MEETING PA 19462 990 2019-01-01 460902111 RTOG FOUNDATION INC RTOG 2157170834 50 S 16TH STREET NO 2800 PHILADELPHIA PA 19102 WALTER J CURRAN JR CHAIRMAN 2157170834 2020-11-13 1 CONNIE M LIRA P00481097 2156433900 2020-11-13 67.137.57.251 2020-11-13 10:40:30 ES P 59AF7F7AE0AD7FB228FE1884CD01039D19CBB9C6 3D28AD700226ABC277D523B23B4B43F613188434 2019 2021-01-29 14:40:06Z X WALTER J CURRAN JR 50 S 16TH STREET NO 2800 PHILADELPHIA PA 19102 6954872 0 X WWW.RTOG.ORG X 2012 PA TO ORGANIZE & PROVIDE FUNDING FOR MULTI-CENTER CLINICAL RESEARCH ACTIVITIES IN ONCOLOGY. 9 9 0 11 0 0 7310029 4992910 2334727 1961679 11 14 302 269 9645069 6954872 0 0 0 0 0 0 0 0 0 9286665 8588379 9286665 8588379 358404 -1633507 4229460 2877464 1787506 2079116 2441954 798348 X THE MISSION OF RTOG FOUNDATION, INC. (RTOG) IS TO: (1) IMPROVE THE SURVIVAL OUTCOME AND QUALITY OF LIFE OF ADULTS WITH CANCER THROUGH THE CONDUCT OF HIGH-QUALITY CLINICAL TRIALS. (2) EVALUATE NEW FORMS OF RADIOTHERAPY DELIVERY AND TEST NEW SYSTEMIC AND TARGETED THERAPIES IN CONJUNCTION WITH RADIOTHERAPY IN THE CONTEXT OF CLINICAL RESEARCH. (3) PARTICIPATE AS ONE OF THREE MEMBER ORGANIZATIONS IN THE ACTIVITIES OF NRG ONCOLOGY FOUNDATION. (4) DEVELOP AND CONDUCT PRACTICE-CHANGING CLINICAL TRIALS FOR THE NCI NATIONAL CLINICAL TRIAL NETWORK (NCTN) THROUGH RTOG'S MEMBERSHIP IN NRG ONCOLOGY. (5) DEVELOP AND CONDUCT INDUSTRY-SUPPORTED CLINICAL TRIALS THAT ARE IMPORTANT TO RTOG'S RESEARCH MISSION. (6) PROVIDE FUNDING FOR BASIC, CLINICAL, AND TRANSLATIONAL INVESTIGATORS TO COLLABORATE WITH RTOG IN THE DEVELOPMENT OF BOTH BIOLOGIC AND BIOPHYSICAL TARGETED THERAPIES. (7) SUPPORT YOUNG INVESTIGATORS FROM MANY DISCIPLINES WITHIN THE RTOG RESEARCH ENTERPRISE THROUGH FELLOWSHIPS AND VARIOUS AWARDS. 0 0 7339728 0 1961679 1) IMPROVE THE SURVIVAL OUTCOME AND QUALITY OF LIFE OF ADULTS WITH CANCER THROUGH THE CONDUCT OF HIGH-QUALITY CLINICAL TRIALS 2) EVALUATE NEW FORMS OF RADIOTHERAPY DELIVERY AND TEST NEW SYSTEMIC AND TARGETED THERAPIES IN CONJUNCTION WITH RADIOTHERAPY IN THE CONTEXT OF CLINICAL RESEARCH 3) PARTICIPATE AS ONE OF THREE MEMBER ORGANIZATIONS IN THE ACTIVITIES OF NRG ONCOLOGY FOUNDATION 4) DEVELOP AND CONDUCT PRACTICE-CHANGING CLINICAL TRIALS FOR THE NCI NATIONAL CLINICAL TRIAL NETWORK (NCTN) THROUGH RTOG'S MEMBERSHIP IN NRG ONCOLOGY 5) DEVELOP AND CONDUCT INDUSTRY-SUPPORTED CLINICAL TRIALS THAT ARE IMPORTANT TO RTOG'S RESEARCH MISSION 6) PROVIDE FUNDING FOR BASIC, CLINICAL, AND TRANSLATIONAL INVESTIGATORS TO COLLABORATE WITH RTOG IN THE DEVELOPMENT OF BOTH BIOLOGIC AND BIOPHYSICAL TARGETED THERAPIES 7) SUPPORT YOUNG INVESTIGATORS FROM MANY DISCIPLINES WITHIN THE RTOG RESEARCH ENTERPRISE. 7339728 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X 9 9 0 0 0 0 0 0 0 1 0 0 0 1 1 1 1 0 0 0 0 0 PA X THE ORGANIZATION 2157170834 50 S 16TH STREET NO 2800 PHILADELPHIA PA 19102 X WALTER J CURRAN JR MD CHAIR 1.00 X X 0 0 0 MITCHELL MACHTAY MD PRESIDENT 5.00 X X 0 0 0 HAK CHOY MD DIRECTOR - LEFT JUNE 2020 1.00 X 0 0 0 JAMES DIGNAM MD DIRECTOR 1.00 X 0 0 0 JEFF MICHALSKI MD MBA DIRECTOR 1.00 X 0 0 0 SETH A ROSENTHAL MD DIRECTOR 1.00 X 0 0 0 MARIA WERNER-WASIK MD DIRECTOR 1.00 X 0 0 0 QUYNH LE MD DIRECTOR 1.00 X 0 0 0 FELIX FENG MD DIRECTOR 1.00 X 0 0 0 0 0 0 0 0 0 0 0 4109263 883647 4992910 CONTRACT REVENUE 900099 1961679 1961679 1961679 14 14 REIMBURSEMENTS 621500 269 269 269 6954872 1961679 0 283 X 11867 11867 17390 17390 863555 86224 777331 11225 9515 1710 11900 11900 129535 55985 73550 35424 1238 34186 30571 30571 RESEARCH PROJECTS 6923781 6923781 SITE EXPENSES 300532 300532 PURCHASES 251085 251085 DUES & SUBSCRIPTIONS 1514 1514 8588379 7339728 1248651 0 2251308 694252 9917 9931 1968235 2173281 4229460 2877464 1787506 2079116 1787506 2079116 X 2441954 798348 2441954 798348 4229460 2877464 -1633507 -10099 0 X 0 0 0 X 11936635 12286004 8011850 7310029 4992910 44537428 11936635 12286004 8011850 7310029 4992910 44537428 5173424 39364004 3 11 14 28 10728 8163 4051 302 269 23513 44560969 4296406 0.88340 0.87300 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: REIMBURSEMENTS - 2015 AMOUNT: $ 10,728. 2016 AMOUNT: $ 8,163. 2017 AMOUNT: $ 4,051. 2018 AMOUNT: $ 302. 2019 AMOUNT: $ 269. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED FORM 990, PART VI, SECTION A, LINE 8B NO BOARD COMMITTEES HAVE BEEN FORMED AS OF THIS TIME. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY AN INDEPENDENT ACCOUNTING FIRM. THE RETURN WILL THEN BE REVIEWED BY THE SECRETARY-TREASURER AND APPROVED. THE RETURN WILL THEN BE MADE AVAILABLE FOR ALL DIRECTORS PRIOR TO ITS FILING. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY APPLIES TO DIRECTORS, PRINCIPAL OFFICER AND MEMBERS OF THE BOARD OF DIRECTORS (INTERESTED PERSON). IN CONNECTION WITH ANY ACTUAL OR POSSIBLE CONFLICT OF INTEREST, AN INTERESTED PERSON MUST DISCLOSE THE EXISTENCE OF THE FINANCIAL INTEREST AND BE GIVEN THE OPPORTUNITY TO DISCLOSE ALL MATERIAL FACTS TO THE DIRECTORS CONSIDERING THE PROPOSED TRANSACTION OR ARRANGEMENT. AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND ALL MATERIAL FACTS, AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE INTERESTED PERSON SHALL LEAVE WHILE THE DETERMINATION OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON BY THE REMAINING BOARD MEMBERS WHO SHALL DETERMINE IF A CONFLICT OF INTEREST EXISTS. IF THE REMAINING MEMBERS DETERMINE THAT AN ACTUAL CONFLICT EXISTS, THE INTERESTED PERSON WILL BE INFORMED OF THAT AND PROVIDED AN OPPORTUNITY TO EXPLAIN. THE REMAINING MEMBERS WILL TAKE DISCIPLINARY ACTION BASED ON THE INTERESTED PERSON'S RESPONSE AND/OR FURTHER INVESTIGATION WARRANTED BY THE CIRCUMSTANCES. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE MADE AVAIALABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 11G SUB-AWARD PROFESSIONAL SERVICES: PROGRAM SERVICE EXPENSES 80,384. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 80,384. STUDY TEAM SERVICES: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 359,960. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 359,960. CONTRACTED RT QA REVIEWS: PROGRAM SERVICE EXPENSES 5,840. MANAGEMENT AND GENERAL EXPENSES 271,622. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 277,462. BIOSPECIMEN BANK: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 108,249. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 108,249. OTHER PROFESSIONAL AND CONTRACTED SERVICES: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 37,500. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 37,500.